Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Aug 22:14:309.
doi: 10.1186/1472-6882-14-309.

In vitro biological evaluation of eight different essential oils against Trypanosoma cruzi, with emphasis on Cinnamomum verum essential oil

Affiliations

In vitro biological evaluation of eight different essential oils against Trypanosoma cruzi, with emphasis on Cinnamomum verum essential oil

Camila Maria O Azeredo et al. BMC Complement Altern Med. .

Abstract

Background: Essential oils (EOs) are complex mixtures of secondary metabolites from various plants. It has been shown that several EOs, or their constituents, have inhibitory activity against trypanosomatid protozoa. Thus, we analyzed the biological activity of different EOs on Trypanosoma cruzi, as well as their cytotoxicity on Vero cells.

Methods: The following EOs were evaluated on T. cruzi epimastigote forms: Cinnamomum verum, Citrus limon, Cymbopogon nardus, Corymbia citriodora, Eucalyptus globulus, Eugenia uniflora, Myrocarpus frondosus, and Rosmarinus officinalis. Inhibitory activity against T. cruzi (IC50/24 h) and cytotoxicity against Vero cells (CC50/24 h) were evaluated by the MTT assay. The EO of C. verum was selected for further evaluation against trypomastigotes and intracellular amastigotes, as well as on parasite metacyclogenesis. Constituents of C. verum EO were identified by GC-MS. One-way ANOVA statistical analysis was performed with GraphPad version 5.01.

Results: Cinnamomum verum EO was the most effective against T. cruzi epimastigotes (IC50/24 h = 24.13 μg/ml), followed by Myrocarpus frondosus (IC50/24 h = 60.87 μg/ml) and Eugenia uniflora (IC50/24 h = 70 μg/ml). The EOs of C. citriodora, E. globulus, and R. officinalis showed no activity at concentrations up to 300 μg/ml. Incubation of T. cruzi metacyclic trypomastigotes and intracellular amastigotes with C. verum EO resulted in IC50/24 h values of 5.05 μg/ml and 20 μg/ml, respectively. Therefore, trypomastigotes are more susceptible than epimastigotes, with selectivity index (SI) about 4.7-fold higher (9.78 and 2.05, respectively). Analysis of C. verum EO by GC-MS showed mainly (E)-cinnamaldehyde (81.52%) and eugenol (16.68%).

Conclusions: C. verum essential oil is effective against T. cruzi (epimastigotes, trypomastigotes and amastigotes) and interferes with the parasite differentiation process in vitro. Thus, it represents a strong candidate for further studies to improve its activity on pathogenic trypanosomatids.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Vero cells infected with T. cruzi and then treated with C. verum essential oil (EO). (A) Control, without treatment; (B) Treatment for 24 h with 20 μg/ml C. verum EO. Note the decrease in amastigote (arrows) number after treatment. Bar = 100 μm.
Figure 2
Figure 2
Number of intracellular amastigotes in Vero cells infected with T. cruzi . Amastigote counting was performed in cultures without treatment (control) or after treatment for 24 h with 10 or 20 μg/ml C. verum EO. (A) Number of total amastigotes per well; (B) Number of amastigotes per cell. ***Statistically different from control and treatment with 10 μg/ml (p < 0.0001); **Statistically different from control and treatment with 10 μg/ml (p < 0.0029).

References

    1. World Health Organization (WHO): Chagas disease (American trypanosomiais) fact sheet n° 340, updated March 2014. [http://www.who.int/mediacentre/factsheets/fs340/en/]. Accessed August 06, 2014
    1. Urbina JA. Specific chemotherapy of Chagas disease: relevance, current limitations and new approaches. Acta Trop. 2010;115:55–68. doi: 10.1016/j.actatropica.2009.10.023. - DOI - PubMed
    1. Coura JR. Chagas disease: what is known and what is needed. A background article. Mem Inst Oswaldo Cruz. 2007;102:113–122. - PubMed
    1. Teixeira AR, Nitz N, Guimaro MC, Gomes C, Santos-Buch CA. Chagas disease. Postgrad Med J. 2006;82:788–798. doi: 10.1136/pgmj.2006.047357. - DOI - PMC - PubMed
    1. Coura JR. Present situation and new strategies for Chagas disease chemoteraphy- a proposal. Mem Inst Oswaldo Cruz. 2009;104:549–554. - PubMed
Pre-publication history
    1. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1472-6882/14/309/prepub

Publication types

MeSH terms

LinkOut - more resources